Human Polyclonal RARA Ab
- Known as:
- Human Polyclonal RARA Antibody
- Catalog number:
- a0370
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ABclonal
- Gene target:
- Human Polyclonal RARA
Related genes to: Human Polyclonal RARA Ab
- Gene:
- RARA NIH gene
- Name:
- retinoic acid receptor alpha
- Previous symbol:
- -
- Synonyms:
- RAR, NR1B1
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-09
- Date modifiied:
- 2019-04-23
Related products to: Human Polyclonal RARA Ab
Related articles to: Human Polyclonal RARA Ab
- bacteremia is associated with high mortality. Whether cefazolin or an antistaphylococcal penicillin should be preferred for the treatment of methicillin-susceptible bacteremia is unclear. - Source: PubMed
Lee Todd CBarina Lauren AWalls GenevieveGoodman Anna LYahav DafnaCheng Matthew PBonten MarcBowen Asha CBoyles TomDaneman NickEkkelenkamp Miquel BGhanem-Zoubi NesrinHensgens Marjolein P MJager Nynke G LKaasch Achim JKouijzer Ilse J ELewis Roger JLumley ThomasLye David CMcDonald Emily GMcKew GenevieveMcLean Alistair R DMcMullan Brendan JMcQuilten Zoe KMorpeth Susan CPaterson David LRoberts Jason ARobinson J OwenSaito HirokiScarborough MatthewTen Oever JaapTurner Rebecca MTverring Jonasvan Hal Sebastiaan JWebb Steve AWhiteway Lynda MArias Cesar AHenderson AndrewHeriot George SSnelling Tom LAfra KevinAli Shabinah SAmit SharonAnagnostou Nicholas AArchuleta SophiaAston Stephen JAthan EugeneBaharav NadavBai Anthony DBarber Bridget EBaskaran AbinayahBerkeley Michelle M ABest Emma JBhilave Nilesh RBloomfield Max GBond Katherine ABostock JenniferBotheras Carly LBoyd Mark ABradshaw Sophia M EBriggs Elizabeth JBritton Philip NCampbell Anita JCarr Beau ZChancellor James AChen KevinCheong Elaine YChew Ka LipChia Po YingChomba RispahChong Brian S WClews Chris J NCohen Jonathan MCommons Robert JCutfield TimDaley PeterDaniel Diane SDavies JaneDe ParthaDenholm Justin TDi Virgilio MiaDishon-Benattar YaelDotel RavindraDuan Erick HEasom NicholasEliakim-Raz NoaEngland Michelle MFahmy MarkFindlater Aidan RFlanagan Katie LFoo Ethan Z JFoo HongForster Daniel PFralick MichaelFrazer Jaimie LGador-Whyte Andrew PGarnham KatherineGerman Greg JGhosh NiladriGisolf Elisabeth HGiulieri Stefano GGoulding Susan RGrant Jennifer MGregson DanielGrimwade Kate CGrupper MordechaiGuy Stephen DGwee AmandaHall Victoria GHardy Erica JHarris David JHatcher JamesHobbs Mark RHolmes Natasha EHowden Benjamin PHuggan Paul JJennings Zoe AJohnstone JennieJuniper ThomasKalimuddin ShirinKamfose MusaiwaleKandel ChristopherKelly Matthew JKozak Robert AKümin MichelleLamontagne FrancoisLau Jillian S YLee Ivor RusselLin Ray JLindsay DaisyLlewelyn Martin JLongtin YvesLother Sylvain ALuey Christopher EMacFadden Derek RMahony Andrew AMalden CatherineMalhamé IsabelleManning Laurens AMarks MichaelMartin Leslie JMatthews Gail VMcGann Patrick HMcMahon James HMelon AlexandraMenon VidthiyaMertz DominikMeyer Michael PMolton James SMora Jocelyn MMoran EdMortimer Leanne MMotaganahalli SatwikMuller Matthew PMunro Alasdair P SMurray Fionnuala AMurthy SrinivasNagendra VanathiNel HencoNew David W JNguyen ViNorton GraceNorton Katherine MNourse Clare BNye Clemency J SO'Callaghan KevinO'Sullivan Matthew V NOng Sean W XOtu Akaninyene AOwen MelissaPapenburg JesseParkes Leighanne OPaul MicalPerez-Patrigeon SantiagoPetersiel NetaPetrella LinaPett Sarah LPham DavidPiazzese Chiara JPoulin SebastienRehak RenataRennert-May ElissaRichards Alexander JRogers Benjamin ASahng EunaSalada BrendaScheuerman OdedSchneider KellieSchulz Thomas RSchwartz Kevin LSimos Peter ASingh HarsimranSinkeler Fleur SSmith SimonSmith Benjamin JSmith Stephanie WSomayaji RanjaniSommerville ChristineSong Rima X JSowden David CStark Michael JStone Neil R HStrunk TobiasSud ArchanaSwe Khine PSymons Caitlin RTan Yen EeTen Doesschate ThijsThien Siew YeeThomas AshmithaTrad Mohamad-AliTramontana Adrian RTsang Jennifer L YUlett KimberlyUnderwood Jonathanvan Welzen Berend JVazquez-Grande GloriaVelasquez Reyes Diana CVerberk Janneke D MVoss Lesley MWard DeniseWebb Rachel HWhitmore Timothy JWieder-Finesod AnatWilson Heather LWilson Evan WWong Hei ManWong She KateWuerz TerenceYamamura Deborah LYeoh AlastairYow Boris Long HeiDymock MichaelMahar Robert KMcGlothlin AnnaMarsh Julie ADavis Joshua STong Steven Y C - Acute promyelocytic leukemia (APL) is a highly curable form of acute myeloid leukemia (AML) when treated early with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Resource constraints in low- and middle-income countries (LMICs) may affect results. This study examined the clinical characteristics and outcomes of pediatric patients with APL receiving an ATRA-ATO-based regimen. The retrospective review included 1- to 16-year-olds diagnosed between January 2019 and December 2022. Morphology and PML-RARA detection by fluorescence in situ hybridization (FISH) confirmed the diagnosis. Patients were stratified by initial white cell count (WCC) (low-risk <10×109/L; high-risk ≥10×109/L). Data were retrieved from electronic medical records. Event-free survival (EFS) rates were obtained using the Kaplan-Meier analysis. Fifty patients (mean age: 10.7 y; 56% male) were evaluated. Low-risk was 32%, and high-risk was 68%. Thrombocytopenia and hypofibrinogenemia were common. All patients had PML-RARA FISH-positives, and 100% of evaluated patients attained morphologic and molecular remissions. Eleven (22%) patients died, mostly from hemorrhage. Abandonment and relapses were observed in 10% and 8% of patients, respectively. Two-year EFS was 60% (low-risk 81%; high-risk 50%). The ATRA-ATO regimen showed substantial remission rates, but early deaths remain a concern. Increased survival rates in resource-constrained environments require improved early detection, referral, and supportive care. - Source: PubMed
Publication date: 2026/06/15
Rafiq NailaPathan Ghulam QMuhammad SadiaMansoor Neelum - - Source: PubMed
Publication date: 2026/06/12
Pestana MadalenaMota Dória HugoGregório TatianaMadureira Ana MargaridaAbreu Nélia - This study investigates the concentrations of trace elements and assesses associated health risks in two Ramsar sites of western Nepal: Lakes Rara and Ghodaghodi. Water samples were collected during the 2019 pre-monsoon and post-monsoon seasons from sites selected according to land use patterns, potential stressors, and accessibility. The concentrations of 12 trace elements (Al, V, Cr, Mn, Fe Co, Ni, Cu, Zn, Cd, Pb, and As) were determined using Inductively Coupled Plasma-Mass Spectrometry. The enrichment factor (EF) was computed to evaluate anthropogenic influences. Additionally, we calculated the metal index (MI), potential ecological risk index (RI), and health risks, encompassing both non-carcinogenic and carcinogenic effects. Iron was the most prevalent trace element across both lakes, followed by aluminium. Water from Ghodaghodi exhibited significant enrichment of Cr, Ni, Zn, As, and Cd, while only As and Cd were highly enriched in Rara. The metal index (MI) values of all the trace elements except Fe and Mn are less than unity in both the lakes. This study further indicates that there are no ecological and non-carcinogenic health risks from both lake waters. However, the carcinogenic risk for As, Cd, Pb, and Cr was "very low" via dermal contact, whereas the risk from ingestion ranged from "very low" to "medium" in both lakes. - Source: PubMed
Publication date: 2026/06/09
Bhatta RitaGurung SmritiJoshi RajendraTuladhar ShrijaRegmi DikshyaKafle Babi KumarDahal Bed ManiRaut NaniKafle Kumud RajKayastha RabindraPrasad ArchanaTripathee LekhendraPaudyal RukumeshGuo JunmingKang ShichangSharma Chhatra Mani - Nucleophosmin 1 (NPM1) gene aberrations are among the most common genetic alterations in acute myeloid leukemia (AML). NPM1 mutations (NPM1c), detected in 30-40% of adult AML cases, are well-characterized and associated with distinct clinical and molecular features. In contrast, NPM1 rearrangements (NPM1-r), involving rare fusion partners such as MLF1, CCDC28A, HAUS1, and RARA, are much less common and have historically been poorly understood. However, recent studies have begun to shed light on the molecular mechanisms and clinical characteristics of NPM1-r AML, revealing overlapping features with NPM1c-AML. Both types share key leukemogenic mechanisms, including cytoplasmic mislocalization of NPM1, interaction with XPO1, and sustained HOX gene expression, which drive leukemic transformation. NPM1-r AML may exhibit unique clinical characteristics, including a higher prevalence in younger patients and potentially a poorer prognosis, although further validation in larger cohorts is needed. Therapeutic strategies targeting XPO1 and Menin, which have shown promise in NPM1c-AML, may also hold potential for NPM1-r AML. Continued research is essential to further elucidate the biology of this rare AML subtype and to establish optimized treatment strategies. - Source: PubMed
Publication date: 2026/06/05
Shimosato YukoGoyama Susumu